Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$8.37M$8.37Mderived+47.8% vs Q4 2020 Net Income-$8.62M-$8.62MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$5,659,000+54.5% Operating Incomederived-$7,654,000N/M Operating Cash Flowderived-$9,588,000N/M Free Cash Flowderived-$9,877,000N/M Margins · derivedGross margin67.6%+3.0 pt vs Q4 2020
Operating margin-91.4%+27.7 pt vs Q4 2020
Net margin-102.9%+34.5 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 23, 2022 · 82 d after period end